Mentioned in ?
References in periodicals archive ?
SomatoKine(R) is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed's most advanced product, SomatoKine(R), is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed Incorporated (Nasdaq: INSM) today provided an update on the Company's ongoing pivotal Phase III clinical trial evaluating SomatoKine(R) (rhIGF-I/rhIGFBP-3) in children with severe short stature due to growth hormone insensitivity syndrome (GHIS).

Full browser ?